

18 November 2019

December 2019 Pharmaceutical Schedule Dispatch

This dispatch email is provided to pharmacists as an early notification of the changes to be announced in the **December 2019** Update to the Pharmaceutical Schedule.

New listings

- Alectinib (Alecensa) cap 150 mg – Retail pharmacy-Specialist – Special Authority (p'code 2574152)
- Amsacrine (Amsidine) inj 50 mg per ml, 1.5 ml ampoule – PCT only – Specialist – S29 (p'code 2577437)
- Capsaicin (Rugby Capsaicin Topical Cream) crm 0.025%, 60 g OP – Special authority – Retail pharmacy – S29 (p'code 2578409)
- Chloramphenicol (Devatis) eye oint 1%, 5 g OP (p'code 2576902)
- Clopidogrel (Clopidogrel Multichem) tab 75 mg (p'code 2567997)
- Danazol (Mylan) cap 100 mg – S29 and wastage claimable (p'code 2577208)
- Dosulepin [dothiepin] hydrochloride (Dosulepin Mylan) cap 25 mg – Subsidy by endorsement, safety medicine; prescriber may determine dispensing frequency – S29 and wastage claimable (p'code 2578905)
- Enteral feed with fibre 0.83 kcal/ml (Nutrison 800 Complete Multi Fibre) liquid, 1,000 ml OP – Special Authority – Hospital pharmacy [HP3] (p'code 2572982)
- Ocrelizumab (Ocrevus) inj 30 mg per ml, 10 ml vial – Special Authority – Retail pharmacy (p'code 2540789)
- Pegaspargase (Oncaspar LYO) inj 750 iu per ml, 5 ml vial – PCT only – Special Authority – S29 (p'code 2578158)
- Pharmacy services (BSF Flecainide Teva) brand switch fee – may only be claimed once per patient (p'code 2577003)
- Pirfenidone (Esbriet) cap 801 mg – Retail pharmacy-Specialist – Special Authority (p'code 2575833)
- Potassium chloride (Potassium Chloride Aguetant) inj 75 mg per ml, 10 ml – S29 and wastage claimable (p'code 2579243)
- Ropinirole hydrochloride (Ropin) tab 0.25 mg (p'code 2578921)
- Temozolomide (Temaccord) cap 5 mg – Special Authority – Retail pharmacy (p'code 2388278)
- Tranexamic acid (Mercury Pharma) tab 500 mg (p'code 2574020)
- Trastuzumab emtansine inj 100 mg vial (p'code 2444186) and 160 mg vial (p'code 2444194) (Kadcyla), and inj 1 mg for ECP (Baxter) (p'code 2579111) – PCT only – Special – Special Authority

- Venetoclax (Venclexta) tab 10 mg, 14 OP (p'code 2555646); tab 50 mg, 7 OP (p'code 2555654); tab 100 mg, wastage claimable (p'code 2555662) and tab 14 x 10 mg, 7 x 50 mg, 21 x 100 mg, 42 OP (p'code 2555638) – Retail pharmacy-Special – Special authority
- Verapamil hydrochloride (Isoptin Retard) tab long-acting 120 mg – S29 and wastage claimable (p'code 2579391)

Changes to restrictions, chemical names and presentations

- Atazanavir sulphate (Teva) cap 150 mg and 200 mg – removal of Brand Switch Fee
- Dimethyl fumarate (Tecfidera) cap 120 mg and 240 mg – amended note
- Efavirenz with emtricitabine and tenofovir disoproxil (Mylan) tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) – removal of Brand Switch Fee
- Emtricitabine with tenofovir disoproxil (Teva) tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) – removal of Brand Switch Fee
- Flecainide acetate (Flecainide Controlled Release Teva) cap long-acting 100 mg and 200 mg – addition of Brand Switch Fee
- Fingolimod (Gilenya) cap 0.5 mg – amended note
- Meningococcal (groups A, C, Y and W-135) conjugate vaccine (Menactra) inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial – amended restriction
- Methenamine (hexamine) hippurate (Hiprex) tab 1 g – amended chemical name
- Natalizumab (Tysabri) inj 20 mg per ml, 15 ml vial – amended note
- Nivolumab inj 10 mg per ml, 4 ml vial and 10 ml vial (Opdivo) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
- Pembrolizumab inj 25 per ml, 4 ml vial (Keytruda) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
- Pirfenidone (Esbriet) cap 267 mg and tab 801 mg – amended Special Authority criteria
- Rituximab inj 100 mg per 10 ml vial and 500 mg per 50 ml vial (Mabthera) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
- Teriflunomide (Aubagio) tab 14 mg – amended note
- Varicella zoster virus (oka strain) live attenuated vaccine [shingles vaccine] (Zostavax) inj 19,400 PFU prefilled syringe plus syringe – amended restriction

Increased subsidy

Chemical	Presentation	Fully subsidised brands
Ascorbic acid	Tab 100 mg	Cvite
Flecainide acetate	Inj 10 mg per ml, 15 ml ampoule	Tambocor
Lithium carbonate	Tab long-acting 400 mg	Priadel
Methenamine (hexamine) hippurate	Tab 1 g	Hiprex**
Vitamins	Tab (BPC cap strength)	Mvite

** no price change for 1 December 2019, only subsidy increase

Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Furosemide [frusemide]	Tab 40 mg	Apo-Furosemide*	Diurin 40
Povidone iodine	Antiseptic soln 10%, 500 ml	Riodine*	Betadine

*no subsidy changes for these brands for 1 December 2019